 To determine the toxicities, maximum tolerated dose MTD and recommended phase 2 dose of MKC-1 when administered orally, twice daily for 14 days followed by 7 days without dosing, in combination with pemetrexed delivered at its recommended single agent dose to patients with advanced solid tumor malignancies. Also, to determine the antitumor activity, based on the objective response rate and median Progression Free Survival PFS, of oral MKC-1, administered on this schedule in combination with pemetrexed to patients with non small cell lung cancer NSCLC. 